Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Sanofi Aventis
Scientific Title
Randomized, Open-label, Phase 2 Study of SAR408701 Combined With Pembrolizumab and Pembrolizumab Alone in Patients With CEACAM5 and PD-L1 Positive Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)